Andrić, Zoran

Tip

Godina

89 2000 - 2027

Mp-kat.

Godina - raspon

Godina od:

Godina do:

Rezultati 21-40 od 89 Rezultati/stranica

Godina	Naslov	Autor(i)	Tip rezultata	Mp-kat.
2023	RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer (SCLC)	Rudin, CM; Dowlati, A; Chen, Y; Navarro, Mendivil AF; Yang, JC-H; Stojanovic, Goran; Rich, P; Andric, Zoran G ; Wu, Y-L; Chen, H; Zhang, L; Yeung, S; Benzaghou, FM; Paz-Ares, L; Bunn, PA;	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2023	HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome	Tobias, Joshua; Kundi, Michael; Garner-Spitzer, E; Zielinski, Christoph; Maglakelidze, Marina; Andric, Zoran G ; Petrovic, Z; Nagarkar, R; Chawla, T; Chong, LO; Nixon, B; Yavrom, S; Ede, NJ; Wiedermann, Ursula;	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2023	Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results	Liu, SV; ...; Andric, Zoran G ; ...; (broj, koautora 24)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2023	TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-Small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study	Leal, Ticiana A; ...; Andric, Zoran G ; ...; (broj, koautora 25)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2022	HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer	Maglakelidze, Marina; Ryspayeva, D; Andric, Zoran G ; Petrovic, Zeljko M; Bulat, IV; Nikolic, Ivan V ; Chawla, T; Nagarkar, R; Wiedermann, Ursula; Blumenstein, BA; Chong, LMO; Ede, NJ; Nixon, B; Good, AJ;	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2022	Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2	Goel, Shom; Tan, Antoinette R; Rugo, Hope S; Aftimos, Philippe; Andric, Zoran G ; Beelen, Andrew Paul; Zhang, Jingshan; Yi, John S; Malik, Rajesh K; O'Shaughnessy, Joyce	Naučni članak	22M22 - Međunarodni časopis kategorije M22
2022	Clinical potential of circulating tumor DNA (ctDNA)-based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response to firstline (1L) chemoimmunotherapy in advanced squamous non-small cell lung cancer (sqNSCLC	Ciardiello, F; Feng, Z; Smith, NR; Andric, Zoran G ; Shell, S; Yablonovitch, A; Guezel, G; Scheuenpflug, J	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2022	1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer	Verschraegen, Claire; Andric, Zoran G ; ...; (broj, koautora 20)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2022	Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin (R)) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC)	Ohe, Yuichiro; ...; Andric, Zoran G ; ...; (broj, koautora 17)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2022	Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+NSCLC: Primary Analysis from JAVELIN Lung 100	Reck, M; ...; Andric, Zoran G ; ...; (broj, koautora 19)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2022	Perioperative bevacizumab in the treatment of colorectal cancer in patients with liver metastases	Nikolić, Ivan ; Manojlović, Nebojša ; Andrić, Zoran ; Radosavljević, Davorin ; Ristić, Marija; Kovčin, Vladimir	Naučni članak	51M51 - Vodeći nacionalni časopis kategorije M51
2022	Overweight and obesity in polycystic ovary syndrome: Association with inflammation, oxidative stress and dyslipidaemia	Perović-Blagojević, Iva; Vekić, Jelena ; Macut, Đuro ; Ignjatović, Svetlana ; Miljković-Trailović, Milica ; Zeljković, Aleksandra ; Spasojević-Kalimanovska, Vesna ; Božić-Antić, Ivana ; Bjekić-Macut, Jelica ; Kastratović-Kotlica, Biljana ; Andrić, Zoran ; Ilić, Dušan; Kotur-Stevuljević, Jelena ;	Naučni članak	22M22 - Međunarodni časopis kategorije M22
2022	Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial	Verschraegen, Claire; Andric, Zoran G ; Moiseenko, Fedor; Makharadze, Tamta; Shevnya, Sergii; Oleksiienko, Alona; Ruiz, Eduardo Yanez; Kim, SungHyun; Ahn, KeumYoung; Park, TaeHong; Park, Sijin; Ju, Hana; Ohe, Yuichiro;	Naučni članak	21aM21a - Vodeći međunarodni časopis kategorije M21a
2022	Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial	Peters, Solange; ...; Andric, Zoran G ; ...; (broj, koautora 26)	Naučni članak	21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+
2021	Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C	Dziadziuszko, R; ...; Andric, Zoran G ; ...; (broj, koautora 20)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2021	Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis.	Trukhin, Dmytro; Poddubskaya, Elena; Andric, Zoran G ; Bondarenko, Igor N; Shevnia, Serhii; Zaric, Bojan ; Bellala, Ravishankar; Charoentum, Chaiyut; Perez, Luis; Bullo, Felicitas; Garcia, Fernanda;	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2021	Polycystic Ovary Syndrome: A Contemporary Clinical Approach	Bjekić-Macut, Jelica ; Vukašin, Tamara; Velija-Ašimi, Zelija; Bureković, Azra; Zdravković, Marija ; Andrić, Zoran ; Branković, Marija ; Crevar-Marinović, Slobodanka; Mandić, Tatjana; Stanojlović, Olivera ; Vojnović-Milutinović, Danijela ; Livadas, Sarantis; Mastorakos, George;	Naučni članak	22M22 - Međunarodni časopis kategorije M22
2021	HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction	Maglakelidze, Marina; ...; Andric, Zoran G ; Nikolic, Ivan V ; ...; Radosavljevic, Davorin Z ; Petrovic, Zeljko M; ...; (broj, koautora 16)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2021	IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1-Selected NSCLC	Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 20)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.
2021	565Tip A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2-breast cancer	Abramson, V; ...; Andric, Zoran G ; Milovic-Kovacevic, Marijana M ; Trifunovic, Jasna D; ...; (broj, koautora 16)	Konferencijski rad	Mp kategorija će biti prikazana naknadno.